Suppr超能文献

地洛瑞林剂量对中枢性性早熟治疗的影响。

Effect of deslorelin dose in the treatment of central precocious puberty.

作者信息

Pescovitz O H, Barnes K M, Cutler G B

机构信息

Department of Pediatrics, Indiana University Medical Center, Indianapolis 46202.

出版信息

J Clin Endocrinol Metab. 1991 Jan;72(1):60-4. doi: 10.1210/jcem-72-1-60.

Abstract

Central precocious puberty is effectively treated with long-acting LHRH analogs (LHRHas). Although at least six LHRHas have now been used in children, there have been no studies to determine the least effective dose of any of these analogs. We sought to determine the effect of decreasing an efficacious dose of deslorelin (D-Trp6-Pro9-NEt-LHRH) on basal and LHRH-stimulated gonadotropins, estradiol levels, and the rates of linear growth and skeletal maturation in subjects with central precocious puberty. Twenty-nine children with central precocious puberty were enrolled in a double blinded study. All subjects were treated for the initial 3 months with deslorelin at a dose (4 micrograms/kg.day, sc) known to suppress gonadotropins, linear growth velocity, and the rate of skeletal maturation. After 3 months, the subjects were randomly assigned to receive one of three daily sc doses of deslorelin: 4 micrograms/kg (n = 9), 2 micrograms/kg (n = 11), or 1 micrograms/kg (n = 9). They were treated at this dose in double blinded fashion for 15 months, after which time they resumed therapy at a dose of 4 micrograms/kg.day for an additional year. The children in the three groups did not differ in terms of chronological age, bone age, pretreatment growth rate, or Tanner stage at the onset of therapy. Similarly, there were no differences in the clinical and hormonal responses to the first 3 months of LHRHa therapy (4 micrograms/kg.day). During the 15-month period at the three different doses, the three dose groups could not be distinguished from each other in terms of pubertal stage, linear growth velocity, rate of skeletal maturation, sex steroid levels, mean LH or FSH levels, or peak FSH response to LHRH stimulation or to a dose of deslorelin. In contrast, the peak LH response to LHRH stimulation was highest in children treated with the lowest dose (1 micrograms/kg.day; P less than 0.025, by multiple analysis of variance). In addition, the peak LH response to a dose of deslorelin (the LHRHa test) was higher in children treated with 1 micrograms/kg.day than in those treated with 4 micrograms/kg.day (P less than 0.04). In summary, the LHRHa test is a sensitive means for detecting activation of the hypothalamic-pituitary-gonadal axis, and deslorelin at a dose of 1 micrograms/kg.day results in less gonadotropin suppression than a dose of 4 micrograms/kg.day.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

长效促性腺激素释放激素类似物(LHRHas)可有效治疗中枢性性早熟。尽管目前至少有六种LHRHas已用于儿童,但尚无研究确定这些类似物中任何一种的最低有效剂量。我们试图确定降低有效剂量的地洛瑞林(D-色氨酸6-脯氨酸9-乙基-LHRH)对中枢性性早熟患者基础及LHRH刺激的促性腺激素、雌二醇水平、线性生长速率和骨骼成熟速率的影响。29名中枢性性早熟儿童参加了一项双盲研究。所有受试者最初3个月接受已知可抑制促性腺激素、线性生长速度和骨骼成熟速率的剂量(4微克/千克·天,皮下注射)的地洛瑞林治疗。3个月后,受试者被随机分配接受三种每日皮下注射剂量的地洛瑞林之一:4微克/千克(n = 9)、2微克/千克(n = 11)或1微克/千克(n = 9)。他们以双盲方式按此剂量治疗15个月,之后恢复以4微克/千克·天的剂量治疗额外一年。三组儿童在治疗开始时的实际年龄、骨龄、治疗前生长速率或坦纳分期方面无差异。同样,对LHRHa治疗的前3个月(4微克/千克·天)的临床和激素反应也无差异。在三种不同剂量的15个月期间,三个剂量组在青春期阶段、线性生长速度、骨骼成熟速率、性类固醇水平、平均LH或FSH水平,或对LHRH刺激或地洛瑞林剂量的峰值FSH反应方面无法相互区分。相比之下,在接受最低剂量(1微克/千克·天)治疗的儿童中,对LHRH刺激的峰值LH反应最高(经多因素方差分析,P < 0.025)。此外,接受1微克/千克·天治疗的儿童对地洛瑞林剂量(LHRHa试验)的峰值LH反应高于接受4微克/千克·天治疗的儿童(P < 0.04)。总之,LHRHa试验是检测下丘脑-垂体-性腺轴激活的敏感方法,1微克/千克·天剂量的地洛瑞林导致的促性腺激素抑制作用低于4微克/千克·天剂量。(摘要截短至250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验